QDELのチャート
QDELの企業情報
| symbol | QDEL |
|---|---|
| 会社名 | Quidel Corp. （キデル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: In Vitro_In Vivo Diagnostic Substances |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 クイーデル(Quidel Corporation)は診断テストソリューションの開発、製造及び販売に従事する会社である。診断テストソリューションはイムノアッセイ、分子アッセイ、ウイルス学、および特殊製品の4つの製品カテゴリに分かれる。同社は医師、病院、臨床検査室、リファレンスラボラトリー、大学、小売クリニック、薬局、ウェルネススクリーニングセンターでのプロフェッショナルな使用のために、エンドユーザーおよびディストリビューターに直接製品を販売する。診断ソリューションは伝染病、女性健康、胃腸疾患、自己免疫疾患、骨の健康および甲状腺疾患を含む疾患および他の病状の検出および診断を援助する。同社は「Quidel」、「QuickVue」、「QuickVue +」、「MicroVue」、「FreshCells」、「D3 FastPoint」、「Super E-Mix」、「ELVIS」、「Sofia」、「Quidel Molecular」、「Amplivue」、「Lyra」および「Thyretain」を含むブランドで診断テストソリューションを提供する。 キデルは、米国の医療関連会社。病状や疾患を医療現場で素早く発見するための臨床検査薬や高速診断用品の発見、開発、製造、販売を手掛ける。製品は、婦人科と感染病分野を中心に、急性疾患や慢性疾患の診断用に使用される。本社はカリフォルニア州サンディエゴ。 QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide. |
| 本社所在地 | 12544 High Bluff Drive Suite 200 San Diego CA 92130 USA |
| 代表者氏名 | Kenneth F. Buechler Kenneth F. Buechler |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 858-552-1100 |
| 設立年月日 | 1979年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 1193人 |
| url | www.quidel.com |
| nasdaq_url | https://www.nasdaq.com/symbol/qdel |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 118.12800 |
| 終値（lastsale） | 63.91 |
| 時価総額（marketcap） | 2495545025.82 |
| 時価総額 | 時価総額（百万ドル） 2524.831 |
| 売上高 | 売上高（百万ドル） 438.08200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2620.537 |
| 当期純利益 | 当期純利益（百万ドル） 20.26900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Quidel Corporation revenues increased from $112M to $272.3M. Net income increased from $2.4M to $30.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from $0.07 to $0.88. |
QDELのテクニカル分析
QDELのニュース
Quidel Non-GAAP EPS of $1.80 beats by $0.37, revenue of $846.1M beats by $73.94M 2023/05/03 20:42:06 Seeking Alpha
Quidel press release (QDEL): Q1 Non-GAAP EPS of $1.80 beats by $0.37.Revenue of $846.1M (-15.4% Y/Y) beats by $73.94M.Growth in non-respiratory revenue for the first quarter was…
QuidelOrtho: 5x Earnings Is Borderline Offensive, Rate Buy At 20x (NASDAQ:QDEL) 2023/04/22 07:41:17 Seeking Alpha
QuidelOrtho presents with attractive business economics. Read more about QDEL here.
Swab and Viral Transport Medium Market is Estimated to Reach US$ 15.6 Billion, Amid Growing Awareness of Proper Sample Collection & Transport | Future Market Insights, Inc. 2023/03/29 13:00:00 Accesswire
NEWARK, DE / ACCESSWIRE / March 29, 2023 / The global Swab And Viral Transport Medium Market could reach about US$ 8.86 billion in 2023, according to FMI''s recent market analysis. By 2033, FMI also anticipated that the market could expand at a 5.8% CAGR and reach a value of US$ 15.60 billion. During the COVID-19 pandemic, there has been a rise in demand for swabs and viral transport mediums. Companies have improved their manufacturing capacity to manufacture items suitable for viral collection, maintenance, and culture as a result of research institutions and labs stepping up their efforts to develop COVID-19 vaccines. Companies in the swab and viral transport medium business are producing inventive kits with vials, double-ended flocked swabs, medications, and other items that avoid bacterial or fungal contamination. They are concentrating on a better solution formulation to stop the growth of bacterial and fungal flora. The market is expanding owing to new viral transport medium solutions.
QuidelOrtho Receives De Novo FDA Authorization for Sofia 2 SARS Antigen+ FIA 2023/03/08 21:05:00 Wallstreet:Online
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA), allowing the company to market its new Sofia 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference 2023/03/02 19:01:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in Orlando, Florida, on March 7, 2023. Douglas Bryant, president and chief executive off
QuidelOrtho: 5x Earnings Is Borderline Offensive, Rate Buy At 20x (NASDAQ:QDEL) 2023/04/22 07:41:17 Seeking Alpha
QuidelOrtho presents with attractive business economics. Read more about QDEL here.
Swab and Viral Transport Medium Market is Estimated to Reach US$ 15.6 Billion, Amid Growing Awareness of Proper Sample Collection & Transport | Future Market Insights, Inc. 2023/03/29 13:00:00 Accesswire
NEWARK, DE / ACCESSWIRE / March 29, 2023 / The global Swab And Viral Transport Medium Market could reach about US$ 8.86 billion in 2023, according to FMI''s recent market analysis. By 2033, FMI also anticipated that the market could expand at a 5.8% CAGR and reach a value of US$ 15.60 billion. During the COVID-19 pandemic, there has been a rise in demand for swabs and viral transport mediums. Companies have improved their manufacturing capacity to manufacture items suitable for viral collection, maintenance, and culture as a result of research institutions and labs stepping up their efforts to develop COVID-19 vaccines. Companies in the swab and viral transport medium business are producing inventive kits with vials, double-ended flocked swabs, medications, and other items that avoid bacterial or fungal contamination. They are concentrating on a better solution formulation to stop the growth of bacterial and fungal flora. The market is expanding owing to new viral transport medium solutions.
QuidelOrtho Receives De Novo FDA Authorization for Sofia 2 SARS Antigen+ FIA 2023/03/08 21:05:00 Wallstreet:Online
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA), allowing the company to market its new Sofia 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference 2023/03/02 19:01:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in Orlando, Florida, on March 7, 2023. Douglas Bryant, president and chief executive off
Quidel Corp. PT Raised to $99 at UBS 2023/02/22 13:03:15 Investing.com
https://www.investing.com/news/pro/quidel-corp-pt-raised-to-99-at-ubs-432SI-3010508
Swab and Viral Transport Medium Market is Estimated to Reach US$ 15.6 Billion, Amid Growing Awareness of Proper Sample Collection & Transport | Future Market Insights, Inc. 2023/03/29 13:00:00 Accesswire
NEWARK, DE / ACCESSWIRE / March 29, 2023 / The global Swab And Viral Transport Medium Market could reach about US$ 8.86 billion in 2023, according to FMI''s recent market analysis. By 2033, FMI also anticipated that the market could expand at a 5.8% CAGR and reach a value of US$ 15.60 billion. During the COVID-19 pandemic, there has been a rise in demand for swabs and viral transport mediums. Companies have improved their manufacturing capacity to manufacture items suitable for viral collection, maintenance, and culture as a result of research institutions and labs stepping up their efforts to develop COVID-19 vaccines. Companies in the swab and viral transport medium business are producing inventive kits with vials, double-ended flocked swabs, medications, and other items that avoid bacterial or fungal contamination. They are concentrating on a better solution formulation to stop the growth of bacterial and fungal flora. The market is expanding owing to new viral transport medium solutions.
QuidelOrtho Receives De Novo FDA Authorization for Sofia 2 SARS Antigen+ FIA 2023/03/08 21:05:00 Wallstreet:Online
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA), allowing the company to market its new Sofia 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference 2023/03/02 19:01:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in Orlando, Florida, on March 7, 2023. Douglas Bryant, president and chief executive off
Quidel Corp. PT Raised to $99 at UBS 2023/02/22 13:03:15 Investing.com
https://www.investing.com/news/pro/quidel-corp-pt-raised-to-99-at-ubs-432SI-3010508
Influenza Diagnostic Global Market Report 2023 2023/02/20 18:46:00 GlobeNewswire
Major players in the influenza diagnostics market are F. Hoffmann-La Roche Ltd, Quidel Corporation, ?h?rm? F??h?r, Abbott Laboratories, Hologic, Becton Dickinson and Company, DiaSorin S.p.A., Luminex Corporation, Meridian Bioscience Inc. Major players in the influenza diagnostics market are F. Hoffmann-La Roche Ltd, Quidel Corporation, ?h?rm? F??h?r, Abbott Laboratories, Hologic, Becton Dickinson and Company, DiaSorin S.p.A., Luminex Corporation, Meridian Bioscience Inc.